Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been assigned an average rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $71.40.

ARCT has been the subject of a number of recent research reports. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Friday, November 8th. Leerink Partners began coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $18.34 on Friday. The firm has a market cap of $496.78 million, a price-to-earnings ratio of -8.26 and a beta of 2.64. The stock has a 50-day simple moving average of $19.91 and a 200-day simple moving average of $23.28. Arcturus Therapeutics has a 52-week low of $14.93 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. During the same period in the previous year, the company earned ($0.61) earnings per share. As a group, equities research analysts predict that Arcturus Therapeutics will post -2.31 earnings per share for the current year.

Insider Activity at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the sale, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This trade represents a 2.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 15.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

Hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. acquired a new position in Arcturus Therapeutics in the 1st quarter valued at approximately $40,000. nVerses Capital LLC bought a new position in Arcturus Therapeutics in the third quarter worth $42,000. Quest Partners LLC boosted its stake in Arcturus Therapeutics by 3,283.5% during the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after buying an additional 3,579 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,038 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Arcturus Therapeutics in the 2nd quarter valued at $142,000. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.